Drug General Information (ID: DDIDHRLI7C)
Drug Name			Clofazimine		Drug Info		Inotuzumab ozogamicin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antiinflammatory Agents				Antineoplastics

Mechanism of Clofazimine-Inotuzumab ozogamicin Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Clofazimine				Inotuzumab ozogamicin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Clofazimine and Inotuzumab ozogamicin

Recommended Action
Management		Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.

References
1	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.